MY190257A - Optimised subcutaneous therapeutic agents - Google Patents
Optimised subcutaneous therapeutic agentsInfo
- Publication number
- MY190257A MY190257A MYPI2014002900A MYPI2014002900A MY190257A MY 190257 A MY190257 A MY 190257A MY PI2014002900 A MYPI2014002900 A MY PI2014002900A MY PI2014002900 A MYPI2014002900 A MY PI2014002900A MY 190257 A MY190257 A MY 190257A
- Authority
- MY
- Malaysia
- Prior art keywords
- residue
- therapeutic agents
- patient
- optimised
- peg
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 238000007920 subcutaneous administration Methods 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206628.8A GB201206628D0 (en) | 2012-04-16 | 2012-04-16 | Subcutaneous administration of PEGylated blood clotting factors |
| GBGB1213712.1A GB201213712D0 (en) | 2012-08-01 | 2012-08-01 | Modified therapeutic agents |
| GBGB1214985.2A GB201214985D0 (en) | 2012-08-22 | 2012-08-22 | Modified therapeutic agents |
| PCT/EP2013/057928 WO2013156488A2 (en) | 2012-04-16 | 2013-04-16 | Optimised subcutaneous therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY190257A true MY190257A (en) | 2022-04-11 |
Family
ID=48190923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014002900A MY190257A (en) | 2012-04-16 | 2013-04-16 | Optimised subcutaneous therapeutic agents |
Country Status (29)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498815B (zh) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| EP3307237A1 (en) * | 2015-06-12 | 2018-04-18 | Laboratoire Français du Fractionnement et des Biotechnologies | Injectable composition of factor vii and fillers |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
| WO2021165226A1 (en) | 2020-02-17 | 2021-08-26 | Biotest Ag | Subcutaneous administration of factor viii |
| EP4138888A1 (en) * | 2020-04-23 | 2023-03-01 | Eli Lilly and Company | Subcutaneous absorption and bioavailability of antibodies |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH596313A5 (cg-RX-API-DMAC7.html) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU5858690A (en) * | 1989-06-14 | 1991-01-08 | Cetus Corporation | Polymer/antibiotic conjugate |
| WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| DE69332928T2 (de) | 1992-09-28 | 2004-05-06 | Research Corp. Technologies, Inc., Tucson | Peptidekupplungsreagentien |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインｃ誘導体 |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| JPH08325270A (ja) * | 1995-05-31 | 1996-12-10 | Bristol Myers Squibb Co | β−ラクタマーゼに対するポリマープロドラッグおよびその使用 |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
| WO1999043357A1 (en) * | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
| RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
| JP5090605B2 (ja) | 2000-05-03 | 2012-12-05 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 凝固因子ｖｉｉの皮下投与 |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| DK1517710T3 (da) * | 2002-06-21 | 2011-07-18 | Novo Nordisk Healthcare Ag | Pegylerede faktor VII-glycoformer |
| DK1596887T3 (da) * | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Faktor VIII-konjugat |
| ES2512499T3 (es) * | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
| US20130137157A1 (en) * | 2003-04-09 | 2013-05-30 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| CN100515422C (zh) | 2004-03-04 | 2009-07-22 | 卫材R&D管理有限公司 | 含有苄脒衍生物的组合物及苄脒衍生物的稳定化方法 |
| CA2571292C (en) * | 2004-06-30 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｆｖｉｉの抱合体 |
| US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| US20090305967A1 (en) * | 2005-08-19 | 2009-12-10 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
| US8133865B2 (en) * | 2006-12-27 | 2012-03-13 | Nektar Therapeutics | von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage |
| WO2008081024A1 (en) | 2007-01-03 | 2008-07-10 | Novo Nordisk Health Care Ag | Subcutaneous administration of coagulation factor viia-related popypeptdes |
| WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| KR20150067772A (ko) | 2007-04-13 | 2015-06-18 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 |
| EP2014299A1 (en) | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
| BRPI0818288A2 (pt) | 2007-10-09 | 2015-04-14 | Polytherics Ltd | Proteínas conjugadas e peptídeos. |
| US8552046B2 (en) | 2007-10-16 | 2013-10-08 | Pharmacyclics, Inc. | Manufacture, compositions and uses of coagulation factor VIIa modulator |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| JP2011517950A (ja) * | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | 第ｉｘ因子の部位特異的修飾 |
| WO2009130602A2 (en) * | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
| CN102083459A (zh) * | 2008-05-23 | 2011-06-01 | 诺沃-诺迪斯克保健股份有限公司 | 包括含有peg化的gla-结构域的蛋白质的低粘度组合物 |
| KR101763559B1 (ko) | 2008-07-21 | 2017-08-14 | 폴리테릭스 리미티드 | 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법 |
| CA2738064C (en) * | 2008-10-15 | 2013-03-19 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
| US20100099616A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
| US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| AU2010281453C1 (en) * | 2009-07-27 | 2019-08-15 | Takeda Pharmaceutical Company Limited | Blood coagulation protein conjugates |
| CN102770449B (zh) * | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| DK2598172T3 (da) * | 2010-07-30 | 2019-07-01 | Baxalta GmbH | Nukleofile katalysatorer til oximforbindelse |
| WO2012088123A1 (en) * | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Polymer-factor vii moiety conjugates |
-
2013
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en not_active Ceased
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 HK HK15100881.5A patent/HK1200695A1/xx unknown
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active Active
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en active Pending
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en not_active IP Right Cessation
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
-
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314B1/en unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
-
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja active Active
-
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en not_active Ceased
-
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY190257A (en) | Optimised subcutaneous therapeutic agents | |
| EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
| BR112021006167A8 (pt) | Partículas de rna compreendendo polisarcosina | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| MX342853B (es) | Tratamiento anti-envejecimiento de la piel. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| NZ710157A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
| MX337830B (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| TR201818927T4 (tr) | Kataterlerde İyileştirme | |
| MX2021013310A (es) | Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles. | |
| HK1209633A1 (en) | Compositions and methods for treating diabetes | |
| JP2015512927A5 (cg-RX-API-DMAC7.html) | ||
| MX2018006299A (es) | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. | |
| MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| Shah et al. | Other routes of protein and peptide delivery: transdermal, topical, uterine, and rectal |